Related Experiment Video

Updated: Aug 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer

Timothy S Collins1, Herbert I Hurwitz

  • 1Department of Medical Oncology, Duke University Medical Center, Durham, NC, USA.

Seminars in Oncology
|February 24, 2005
PubMed

Insights

New therapies targeting tumor angiogenesis, the formation of new blood vessels, are showing promise. Blocking vascular endothelial growth factor (VEGF) with bevacizumab offers a critical proof of principle for inhibiting tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor growth is critically dependent on angiogenesis, the formation of new blood vessels.
  • Angiogenesis is regulated by a complex interplay of pro- and anti-angiogenic factors.
  • Understanding these factors enables the development of therapies to inhibit tumor growth and survival.

Purpose of the Study:

  • To review the biology of angiogenesis in colorectal cancer.
  • To discuss the current status of angiogenesis inhibition in colorectal cancer treatment.

Main Methods:

  • Review of existing literature on angiogenesis in colorectal cancer.
  • Analysis of clinical trial data for angiogenesis inhibitors.

Main Results:

  • Vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis.
  • Monoclonal antibody targeting VEGF (bevacizumab) has demonstrated efficacy in phase III trials.
  • Angiogenesis inhibition represents a validated therapeutic strategy.

Conclusions:

  • Targeting angiogenesis is a viable approach for colorectal cancer treatment.
  • Bevacizumab provides a proof of principle for anti-angiogenic therapies.
  • Further research into angiogenesis pathways may yield novel therapeutic strategies.

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...